GlassScriptPhysician profile
Brookanne J Mickelson
NPI 1013916915
$4,970.15
in general payments reported to CMS, 2019-2025
40 companies · $1,633 in 2025
The $1,633 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $794 · 2022: $414 · 2023: $1,054 · 2024: $1,076 · 2025: $1,633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,762.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,780.42 | 2021-2025 | General - Pain Management, Wavewriter Alpha Prime 16, Intracept |
| Abbvie INC. | $435.86 | 2023-2025 | |
| Pfizer INC. | $330.47 | 2023-2025 | |
| Collegium Pharmaceutical, INC. | $246.12 | 2021-2024 | Belbuca, Belbuca, Xtampza |
| Actelion Pharmaceuticals US, INC. | $228.62 | 2021-2023 | Opsumit, Uptravi |
| Relievant Medsystems, INC. | $148.48 | 2021-2023 | Intracept |
| Abbott Laboratories | $141.72 | 2021-2023 | Proclaim |
| Lundbeck LLC | $133.63 | 2023-2025 | Vyepti |
| Novartis Pharmaceuticals Corporation | $119.32 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $113.86 | 2024 | Camzyos |
| Tonix Medicines, INC. | $94.25 | 2025 | Tonmya |
| Averitas Pharma INC. | $87.79 | 2023-2025 | Qutenza |
| Tactile Systems Technology INC | $79.83 | 2021 | |
| Argenx US, INC. | $79.56 | 2024-2025 | Vyvgart Hytrulo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.88 | 2021-2025 | Relistor |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $74.43 | 2022 | |
| Genentech USA, INC. | $72.59 | 2023-2024 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Nalu Medical, INC. | $67.11 | 2021-2024 | Nalu Neurostimulation System |
| Axsome Therapeutics, INC. | $63.07 | 2025 | Symbravo |
| Redhill Biopharma INC. | $58.92 | 2021-2023 | Movantik |
| Stryker Corporation | $58.59 | 2025 | Optablate |
| Janssen Pharmaceuticals, INC | $57.69 | 2022 | |
| Spr Therapeutics, INC | $41.39 | 2024-2025 | Sprint Pns System |
| Biogen, INC. | $37.85 | 2023-2024 | Skyclarys, Vumerity, Tysabri |
| Emd Serono, INC. | $34.48 | 2023 | Mavenclad |
| Neurocrine Biosciences, INC. | $31.02 | 2023-2025 | Ingrezza, Ongentys |
| Ucb, INC. | $29.38 | 2025 | Rystiggo |
| Grifols USA, LLC | $25.46 | 2024 | Gamunex-C |
| Merz Pharmaceuticals, LLC | $24.49 | 2024 | Xeomin |
| Tanabe Pharma America, INC. | $22.58 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $21.51 | 2021 | |
| Alexion Pharmaceuticals, INC. | $20.67 | 2024 | Ultomiris |
| Ani Pharmaceuticals, INC. | $20.54 | 2025 | Purified Cortrophin Gel |
| Radius Health, INC. | $19.34 | 2025 | Tymlos |
| Recordati_rare_diseases_inc. | $18.05 | 2024 | Signifor Lar, Isturisa |
| Indivior INC. | $16.96 | 2021 | |
| Cycle Pharmaceuticals INC | $16.53 | 2025 | Bafiertam |
| Protega Pharmaceutials INC | $15.98 | 2024 | Roxybond |
| Sobi, INC | $14.16 | 2025 | |
| Amgen INC. | $12.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brookanne Mickelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.